Bradanicline

Bradanicline (INN;^[1] development code TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder.^[2] Phase I clinical trials were completed successfully, and it was in phase II trials.^[3]

Bradanicline

Clinical data
Other names	TC-5619
Identifiers
IUPAC name N-[(2S,3R)-2-(Pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2- carboxamide
CAS Number	639489-84-2
PubChem CID	16727410
IUPHAR/BPS	3969
ChemSpider	20559152
UNII	UM3821998K
KEGG	D10613 Y
ChEMBL	ChEMBL1258006
CompTox Dashboard (EPA)	DTXSID40213778
Chemical and physical data
Formula	C22H23N3O2
Molar mass	361.445 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN2CCC1[C@@H]([C@@H]2CC3=CN=CC=C3)NC(=O)C4=CC5=CC=CC=C5O4
InChI InChI=1S/C22H23N3O2/c26-22(20-13-17-5-1-2-6-19(17)27-20)24-21-16-7-10-25(11-8-16)18(21)12-15-4-3-9-23-14-15/h1-6,9,13-14,16,18,21H,7-8,10-12H2,(H,24,26)/t18-,21-/m0/s1 Key:OXKRFEWMSWPKKV-RXVVDRJESA-N
(verify)

In May 2011, AstraZeneca declined to exercise its right to license the compound.^[4] In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults.^[5] It was being studied for cognitive and memory enhancement.^[6]

Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late-2013.^[7] It was also discontinued for ADHD.^[7]